Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest Operation Pangea Prompts Asian Crackdowns

This article was originally published in PharmAsia News

Executive Summary

As part of the annual global Operation Pangea, coordinated by Interpol to crack down on counterfeit drugs and illicit online sales of medicines and medical devices, South Korea's Ministry of Food and Drug Safety has uncovered more than 800 websites that illegally sell medicines to consumers, while other Asian authorities are also taking action.

You may also be interested in...



Malaysia Steps Up Surveillance Of Counterfeit Drugs

SHANGHAI - The Malaysian Padang Besar Anti-Smuggling Unit seized 12,285 bottles of China-made herb capsules and Chinese medicine at the Malaysian-Thai border in early December, the authorities announced recently

Interpol Seizes Counterfeit Drugs In Southeast Asia; More Measures Mulled

The International Criminal Police Organization confiscated $6.65 million worth of counterfeit HIV/AIDS, malaria and tuberculosis drugs in Southeast Asia, the organization announced at the International Law Enforcement Training Seminar on Combating Counterfeit Drugs Nov. 17 in Phnom Penh, Cambodia

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.

Topics

UsernamePublicRestriction

Register

ID036688

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel